Creative Biolabs attended the 21st BioPharma Drug Discovery Nexus Conference as an exhibitor for the first time on October 22–23.SDAB (Single-Domain Antibodies)"This event, a major hub fo

Creative Biolabs is helping to address the demand on the rise for reliable, scalable, and ethically produced antibodies as the biotech industry continues to innovate.

Creative Biolabs offers top-notch mRNA technology support to fuel emerging therapeutic discoveries.mRNA technology platformmRNA technology platformRece

Creative Biolabs introduces its range of TNFRSF9-related antibody reagents.The growing interest in TNFRSF9 (also known as CD137, 4-1BB) stems from its role as a co-stimulatory receptor on T cells...

Recent industry breakthroughs highlight the role of NHPs as a key factor in achieving more accurate preclinical results. Creative Biolabs has responded to this need by expanding its portfolio of NHP...

Creative Biolabs elaborates on the development mechanisms of DC and mRNA vaccines, two of the most promising cancer vaccine candidates.DC VaccinesThe pursuit

Creative Biolabs significantly contributes to the advancement of oncolytic virus therapy with full-set services and blue-ribbon products.Oncolytic

Creative Biolabs introduces recombinant viral vector development mechanisms and features some essential products.Gene therapy has emerged as a beacon of hope for treating many intractable diseases...

Creative Biolabs elaborates on single-domain antibody (sdAb) development and sequencing, which are designed to support scientists and pharmaceutical companies in their new drug discovery...

A scientist from Creative Biolabs presents the routes they use to manage the development of novel CAR-T, TCR-T, and scFv-TCR T cell therapies.CAR Cell Products

Creative Biolabs is proud to announce its new-year resolution to dive deeper into sourcing professional animal model solutions for neurological disorder studies.

Brain metastases (BrM) are the most common intracranial tumors, mainly originating from lung cancer (40–50% of cases), breast cancer (15–25%), and melanoma (5–20%). Despite treatment with molecularly...

AIDS was first reported by the CDC in 1981, and in 1983, scientists identified human immunodeficiency virus (HIV) infection as the cause of AIDS. Today, more than 40 years later, we have effective...

Gastric cancer (GC) is the fifth most common cancer in the world and one of the leading causes of cancer deaths. According to the global cancer burden data released by the International Agency for...

In order to adapt to their energy needs, tumors exhibit unique metabolic characteristics that allow for the production of ATP in the form of aerobic glycolysis to supply energy for cellular...